Product Name :
SKF86002
Description:
SKF86002 is a p38 MAP kinase inhibitor. SKF86002 inhibits IL-1 beta production by affecting at least two distinct steps in the biosynthesis of this cytokine.
CAS:
72873-74-6
Molecular Weight:
297.35
Formula:
C16H12FN3S
Chemical Name:
6-(4-fluorophenyl)-5-(pyridin-4-yl)-2, 3-dihydroimidazo[2, 1-b]thiazole
Smiles :
FC1C=CC(=CC=1)C1N=C2SCCN2C=1C1C=CN=CC=1
InChiKey:
YOELZIQOLWZLQC-UHFFFAOYSA-N
InChi :
InChI=1S/C16H12FN3S/c17-13-3-1-11(2-4-13)14-15(12-5-7-18-8-6-12)20-9-10-21-16(20)19-14/h1-8H,9-10H2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
SKF86002 is a p38 MAP kinase inhibitor. SKF86002 inhibits IL-1 beta production by affecting at least two distinct steps in the biosynthesis of this cytokine.|Product information|CAS Number: 72873-74-6|Molecular Weight: 297.35|Formula: C16H12FN3S|Synonym:|PTC299|SK and F 86002|SK and F 86002-A(2)|SKF 86002|6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole|SKF86002|Chemical|Chemical Name: 6-(4-fluorophenyl)-5-(pyridin-4-yl)-2, 3-dihydroimidazo[2, 1-b]thiazole|Smiles: FC1C=CC(=CC=1)C1N=C2SCCN2C=1C1C=CN=CC=1|InChiKey: YOELZIQOLWZLQC-UHFFFAOYSA-N|InChi: InChI=1S/C16H12FN3S/c17-13-3-1-11(2-4-13)14-15(12-5-7-18-8-6-12)20-9-10-21-16(20)19-14/h1-8H,9-10H2|Technical Data|Appearance: Solid Power.|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|References:|Khattab M, Van Dongen M, Wang F, Clayton AH. Solvatochromism and linear solvation energy relationship of the kinase inhibitor SKF86002. Spectrochim Acta A Mol Biomol Spectrosc.{{Dantrolene} MedChemExpress|{Dantrolene} Neuronal Signaling|{Dantrolene} Protocol|{Dantrolene} Purity|{Dantrolene} manufacturer|{Dantrolene} Epigenetics} 2017 Jan 5;170:226-33.{{Tecarfarin} MedChemExpress|{Tecarfarin} Technical Information|{Tecarfarin} Description|{Tecarfarin} custom synthesis|{Tecarfarin} Epigenetic Reader Domain} doi: 10.PMID:24580853 1016/j.saa.2016.07.027. PubMed PMID: 27450120.Dai HL, Hu WY, Jiang LH, Li L, Gaung XF, Xiao ZC. p38 MAPK Inhibition Improves Synaptic Plasticity and Memory in Angiotensin II-dependent Hypertensive Mice. Sci Rep. 2016 Jun 10;6:27600. doi: 10.1038/srep27600. PubMed PMID: 27283322; PubMed Central PMCID: PMC4901328.Mizukoshi Y, Takeuchi K, Arutaki M, Takizawa T, Hanzawa H, Takahashi H, Shimada I. Suppression of problematic compound oligomerization by cosolubilization of nondetergent sulfobetaines. ChemMedChem. 2015 Apr;10(4):736-41. doi: 10.1002/cmdc.201500057. PubMed PMID: 25760302; PubMed Central PMCID: PMC4471626.Poulsen JN, Larsen F, Duroux M, Gazerani P. Primary culture of trigeminal satellite glial cells: a cell-based platform to study morphology and function of peripheral glia. Int J Physiol Pathophysiol Pharmacol. 2014 Mar 13;6(1):1-12. PubMed PMID: 24665354; PubMed Central PMCID: PMC3961097.Products are for research use only. Not for human use.|
